EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

The Company’s CEO, Dr Mike Hudson, will engage in a conversation designed especially for private investors. This informal setting offers an opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

Commenting on the event, EDX Medical Group Dr Mike Hudson, said:

“We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders, share our vision and answer any questions investors may have.”

All attendees will have the chance to network over drinks and a buffet.

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes.

EDX Medical targets AIM growth with ultra-accurate cancer diagnostics

EDX Medical Chief Scientific Officer Professor Chris Evans discusses the company’s AIM admission, prostate cancer testing programme in Scotland, and plans to commercialise a range of advanced diagnostic tests.

EDX Medical begins trading on AIM following move from Aquis

EDX Medical has commenced trading on the AIM market of the London Stock Exchange under the ticker EDX, highlighting its growth strategy in cancer and infectious disease diagnostics and its expanding portfolio of personalised healthcare technologies.

EDX Medical seeks AIM admission as it prepares to leave Aquis

EDX Medical has announced plans to transfer its ordinary shares from the Aquis Stock Exchange to AIM, with admission and withdrawal expected to take effect simultaneously on 13 May 2026. The company says the move is intended to improve access to growth capital, investor visibility and share liquidity.

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways to improve early detection and diagnosis of the disease.

EDX Medical raises ÂŁ3.5m to accelerate prostate cancer programme

EDX Medical Group plc has completed a ÂŁ3.5 million fundraising from existing high net worth shareholders, issuing 24,999,999 new ordinary shares at 14p per share.

Search